VANCOUVER, British Columbia, Jan. 05, 2026 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 Labs, Inc. (OTC:FITY) today issues the following clarification regarding its press release dated August 26, 2025, which referenced a potential collaboration with LUNR Aerospace. It is the intent of this press release to clarify and confirm that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace and there is no current intent to do so.  Mr. ...

Core Insights - The partnership between ViRx@Stanford and Fifty1 AI Labs aims to enhance global health security by repurposing existing drugs into antiviral therapies through AI technology [1][2][3] - The initiative, named "BE READI!", focuses on proactive measures to prepare for and respond to emerging pandemics, emphasizing the need for rapid development of antiviral treatments [2][5] - The collaboration is backed by significant funding, including a US$69 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), which supports the development of outpatient antiviral cocktails [4] Company Overview - ViRx@Stanford is dedicated to advancing antiviral drug development and enhancing biosecurity, leveraging cutting-edge AI to accelerate pharmaceutical innovation [6] - Fifty1 AI Labs specializes in AI-driven drug repurposing, focusing on off-patent compounds to create cost-effective therapies that improve patient outcomes [7] Strategic Goals - The partnership aims to build a scalable model for pandemic response, integrating AI and repurposed therapeutics to ensure rapid and equitable access to life-saving treatments [5] - The initiative draws lessons from past pandemics, including the COVID-19 pandemic, which resulted in approximately 10 million deaths, and aims to mitigate similar mortality rates in future outbreaks [3]